ANIX
Anixa Biosciences Inc (ANIX
NASDAQ · Healthcare · Biotechnology · US
$2.77
+0.36%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$2.78
From 52W high−46.93%
Volume315179.00
Market cap$96.30M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$2.78
From 52W high
−46.93%
Volume
315179.00
Market cap
$96.30M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−7.7x
P/E (TTM)
—
RSI (14)
34.8
MomentumView details →
1D Return
+0.36%
YTD Return
−12.98%
SummaryUpdated Jul 1, 2026
Anixa Biosciences, Inc. (NASDAQ:ANIX) is a biotechnology company founded in 1982 and originally incorporated as ITUS Corporation before changing its name in October 2018. Based in San Jose, California, the company has transitioned from its original business focus to become a clinical-stage biotechnology firm developing innovative therapies and vaccines for oncology and infectious diseases. The company went public in 1983 and has since evolved into a research-focused organization targeting critical unmet medical needs through advanced immunotherapy and vaccine technologies.
Similar companies
Latest newsMore news →
Anixa Biosciences was granted a Korean patent for its breast cancer vaccine by the Korean Ministry of Intellectual Property, extending protection through 2040.83d agoAnixa Biosciences received a Notice of Allowance from the Canadian Intellectual Property Office for a patent covering its ovarian cancer vaccine technology.111d ago